Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature

Ahmed Babiker; Lloyd Clarke; Yohei Doi; Ryan K Shields

doi:10.1016/j.diagmicrobio.2019.06.008

Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114856. doi: 10.1016/j.diagmicrobio.2019.06.008. Epub 2019 Jun 24.

Authors

Ahmed Babiker¹, Lloyd Clarke¹, Yohei Doi¹, Ryan K Shields²

Affiliations

¹ Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
² Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: shieldsrk@upmc.edu.

PMID: 31307867
DOI: 10.1016/j.diagmicrobio.2019.06.008

Abstract

Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs.

Keywords: CRE; ESBL; Fosfomycin; UTI; VRE.

Publication types

Review

MeSH terms

Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents / therapeutic use*
Drug Resistance, Multiple, Bacterial / drug effects*
Female
Fosfomycin / therapeutic use*
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Urinary Tract Infections / drug therapy*
Urinary Tract Infections / microbiology
Young Adult

Substances

Anti-Bacterial Agents
Fosfomycin